Transcatheter aortic valve replacement in small aortic annuli: A propensity-matched comparison between intra-annular self-expanding valves and balloon-expandable valves.
Danial Ahmad, Michel Pompeu Sá, Dustin Kliner, Derek Serna-Gallegos, Catalin Toma, Amber Makani, David West, Yisi Wang, Floyd Thoma, Takuya Ogami, Irsa Hasan, Ibrahim Sultan
{"title":"Transcatheter aortic valve replacement in small aortic annuli: A propensity-matched comparison between intra-annular self-expanding valves and balloon-expandable valves.","authors":"Danial Ahmad, Michel Pompeu Sá, Dustin Kliner, Derek Serna-Gallegos, Catalin Toma, Amber Makani, David West, Yisi Wang, Floyd Thoma, Takuya Ogami, Irsa Hasan, Ibrahim Sultan","doi":"10.1016/j.carrev.2025.05.009","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Specific transcatheter aortic valve replacement (TAVR) valve superiority is not established in the small aortic annulus (SAA) population. We sought to compare clinical and echocardiographic characteristics between patients with a SAA who underwent TAVR with either intra-annular self-expanding valves (SEV) or balloon-expandable valves (BEV).</p><p><strong>Methods: </strong>This was an observational, retrospective analysis (2013-2023). SAA was defined as an aortic annulus diameter < 23 mm (maximum) and annulus area ≤ 430 mm<sup>2</sup>. Unmatched and propensity-score matched (PSM) populations were compared.</p><p><strong>Results: </strong>We identified 663 patients with SAA who underwent TAVR with SEV (n = 106) or BEV (n = 557). The PSM cohort (96 pairs) was predominantly female (90.6 % and 87.5 %) with a median age of 82.5 and 81.0 years. No statistically significant differences were observed in VARC-3 outcomes (periprocedural mortality, technical success, device success, clinical efficacy). Higher rates of residual mean gradients >20 mmHg were seen in the BEV group at 30 days (SEV 2.1 % vs BEV 21.9 %, P < 0.001) as well as lower median values of indexed effective orifice area (SEV 0.9 vs 0.6 cm<sup>2</sup>/m<sup>2</sup>). Severe PPM was also more common in the BEV group (SEV 5.2 % vs BEV 21.9 %, P = 0.002). At 2 years, differences in the rates of all-cause death (SE 11.9 % vs BE 17.1 %, P<sub>log-rank</sub> = 0.6794) and stroke (SEV 3.4 % vs BEV 10.2 %, P = 0.7055) were not statistically significant.</p><p><strong>Conclusions: </strong>Intra-annular SEV presented better hemodynamics compared to BEV; however, survival and incidence of stroke were comparable between the groups at 2 years. Potential risk of nonstructural valve deterioration with BEV needs further investigation with longer follow-up.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Revascularization Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.carrev.2025.05.009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Specific transcatheter aortic valve replacement (TAVR) valve superiority is not established in the small aortic annulus (SAA) population. We sought to compare clinical and echocardiographic characteristics between patients with a SAA who underwent TAVR with either intra-annular self-expanding valves (SEV) or balloon-expandable valves (BEV).
Methods: This was an observational, retrospective analysis (2013-2023). SAA was defined as an aortic annulus diameter < 23 mm (maximum) and annulus area ≤ 430 mm2. Unmatched and propensity-score matched (PSM) populations were compared.
Results: We identified 663 patients with SAA who underwent TAVR with SEV (n = 106) or BEV (n = 557). The PSM cohort (96 pairs) was predominantly female (90.6 % and 87.5 %) with a median age of 82.5 and 81.0 years. No statistically significant differences were observed in VARC-3 outcomes (periprocedural mortality, technical success, device success, clinical efficacy). Higher rates of residual mean gradients >20 mmHg were seen in the BEV group at 30 days (SEV 2.1 % vs BEV 21.9 %, P < 0.001) as well as lower median values of indexed effective orifice area (SEV 0.9 vs 0.6 cm2/m2). Severe PPM was also more common in the BEV group (SEV 5.2 % vs BEV 21.9 %, P = 0.002). At 2 years, differences in the rates of all-cause death (SE 11.9 % vs BE 17.1 %, Plog-rank = 0.6794) and stroke (SEV 3.4 % vs BEV 10.2 %, P = 0.7055) were not statistically significant.
Conclusions: Intra-annular SEV presented better hemodynamics compared to BEV; however, survival and incidence of stroke were comparable between the groups at 2 years. Potential risk of nonstructural valve deterioration with BEV needs further investigation with longer follow-up.
背景:特异性经导管主动脉瓣置换术(TAVR)在小主动脉环(SAA)人群中的优势尚未确立。我们试图比较接受TAVR的SAA患者的临床和超声心动图特征,无论是环内自扩瓣膜(SEV)还是球囊可扩瓣膜(BEV)。方法:采用观察性、回顾性分析(2013-2023)。SAA定义为主动脉环直径2。不匹配和倾向分数匹配(PSM)人群进行比较。结果:我们发现663例SAA患者接受了伴有SEV (n = 106)或BEV (n = 557)的TAVR。PSM队列(96对)以女性为主(90.6%和87.5%),中位年龄分别为82.5岁和81.0岁。在VARC-3结局(围手术期死亡率、技术成功、器械成功、临床疗效)方面没有观察到统计学上的显著差异。在30天,BEV组观察到较高的残余平均梯度率bb0 20 mmHg (SEV 2.1% vs BEV 21.9%, P 2/m2)。严重PPM在BEV组中也更为常见(SEV 5.2% vs BEV 21.9%, P = 0.002)。2年时,全因死亡率(SE 11.9% vs BE 17.1%, Plog-rank = 0.6794)和卒中(SEV 3.4% vs BEV 10.2%, P = 0.7055)的差异无统计学意义。结论:与BEV相比,环内SEV具有更好的血流动力学;然而,两组在2年时的生存率和卒中发生率是相当的。BEV非结构性瓣膜恶化的潜在风险需要进一步调查,随访时间更长。
期刊介绍:
Cardiovascular Revascularization Medicine (CRM) is an international and multidisciplinary journal that publishes original laboratory and clinical investigations related to revascularization therapies in cardiovascular medicine. Cardiovascular Revascularization Medicine publishes articles related to preclinical work and molecular interventions, including angiogenesis, cell therapy, pharmacological interventions, restenosis management, and prevention, including experiments conducted in human subjects, in laboratory animals, and in vitro. Specific areas of interest include percutaneous angioplasty in coronary and peripheral arteries, intervention in structural heart disease, cardiovascular surgery, etc.